A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer
This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced biliary cancer.
Advanced Biliary Cancer
DRUG: TQB2450 Injection|DRUG: Anlotinib hydrochloride|DRUG: Oxaliplatin injection|DRUG: Capecitabine tablets|DRUG: Gemcitabine hydrochloride injection
Overall survival (OS), OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 40 weeks
Progression free survival (PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to 24 weeks|Overall response rate (ORR), Percentage of participants achieving complete response (CR) and partial response (PR)., up to 24 weeks|Disease control rate（DCR）, Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 24 weeks|Duration of response（DOR）, The time when the participants first achieved complete or partial remission to disease progression., up to 24 weeks|Progression-free survival at 6 months, Percentage of participants whose PFS has achieved at least 6 months., up to 6 months|Overall survival at 6 months, Percentage of participants whose OS has achieved at least 6 months., up to 6 months|Overall survival at 12 months, Percentage of participants whose OS has achieved at least 12 months., up to 12 months
This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced biliary cancer.